Home/Filings/4/0000899243-18-020207
4//SEC Filing

Pillar Invest Corp 4

Accession 0000899243-18-020207

CIK 0000861838other

Filed

Jul 18, 8:00 PM ET

Accepted

Jul 19, 6:13 PM ET

Size

13.5 KB

Accession

0000899243-18-020207

Insider Transaction Report

Form 4
Period: 2018-07-13
Pillar Invest Corp
Director10% Owner
Transactions
  • Sale

    Common Stock

    2018-07-17$0.99/sh874,505$862,5240 total(indirect: See footnote)
  • Sale

    Common Stock

    2018-07-13$1.05/sh250,500$264,0520 total(indirect: See footnote)
  • Sale

    Common Stock

    2018-07-16$1.01/sh735,771$743,6440 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock

    2018-07-13$1.05/sh250,500$264,0520 total(indirect: See footnote)
  • Sale

    Common Stock

    2018-07-17$0.99/sh874,505$862,5240 total(indirect: See footnote)
  • Sale

    Common Stock

    2018-07-16$1.01/sh735,771$743,6440 total(indirect: See footnote)
Footnotes (6)
  • [F1]The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $1.0350-$1.1000. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  • [F2]Shares sold by Participations Besancon. Participations Besancon is a fund advised by Pillar Invest Corporation ("Pillar GP"). Pillar GP disclaims Section 16 beneficial ownership of the Besancon Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon. Following this transaction, Participations Besancon owns directly 9,825,473 shares of common stock of the Issuer.
  • [F3]The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $0.9601-$1.0500. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  • [F4]Shares sold by Participations Besancon. Pillar GP disclaims Section 16 beneficial ownership of the Besancon Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon. Following this transaction, Participations Besancon owns directly 9,089,702 shares of common stock of the Issuer.
  • [F5]The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $0.9300-$1.0250. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  • [F6]Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. Following this transaction, Pillar II owns directly 9,085,451 shares of common stock of the Issuer.

Issuer

IDERA PHARMACEUTICALS, INC.

CIK 0000861838

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001534428

Filing Metadata

Form type
4
Filed
Jul 18, 8:00 PM ET
Accepted
Jul 19, 6:13 PM ET
Size
13.5 KB